Ardelyx Future Growth

Future criteria checks 6/6

Ardelyx is forecast to grow earnings and revenue by 59.6% and 33.7% per annum respectively. EPS is expected to grow by 59.7% per annum. Return on equity is forecast to be 109% in 3 years.

Key information

59.6%

Earnings growth rate

59.7%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	33.7%
Future return on equity	109.0%
Analyst coverage	Good
Last updated	27 Apr 2024

Recent future growth updates

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24

Recent updates

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14

What To Expect For Ardelyx In The Coming Month

Oct 18

Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position

Oct 04

Ardelyx secures $20M financial deal with HealthCare Royalty on tenapanor potential sale

Jun 30

Ardelyx Is Down, Long Live Ardelyx

Jan 28

Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher

Dec 02

Ardelyx: Indecisive Regulators, Frustrated Company, Gruelling Wait For Investors

Oct 25

Earnings and Revenue Growth Forecasts

NasdaqGM:ARDX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	565	168	172	156	8
12/31/2025	367	7	-1	6	9
12/31/2024	208	-107	-73	-59	10
12/31/2023	124	-66	-90	-90	N/A
9/30/2023	134	-27	-67	-67	N/A
6/30/2023	83	-56	-71	-71	N/A
3/31/2023	63	-66	-87	-87	N/A
12/31/2022	52	-67	-70	-70	N/A
9/30/2022	9	-114	-124	-124	N/A
6/30/2022	5	-135	-133	-133	N/A
3/31/2022	4	-153	-137	-136	N/A
12/31/2021	10	-158	-154	-153	N/A
9/30/2021	11	-151	-133	-131	N/A
6/30/2021	12	-125	-118	-116	N/A
3/31/2021	13	-105	-102	-101	N/A
12/31/2020	8	-94	-82	-81	N/A
9/30/2020	8	-85	-75	-75	N/A
6/30/2020	8	-91	-76	-76	N/A
3/31/2020	6	-91	-85	-85	N/A
12/31/2019	5	-95	-77	-76	N/A
9/30/2019	3	-103	-84	-84	N/A
6/30/2019	0	-104	-91	-90	N/A
3/31/2019	0	-100	-81	-80	N/A
12/31/2018	3	-91	-71	-70	N/A
9/30/2018	45	-53	-47	-47	N/A
6/30/2018	44	-50	-40	-39	N/A
3/31/2018	44	-53	-47	-45	N/A
12/31/2017	42	-64	-68	-65	N/A
9/30/2017	N/A	-106	N/A	-97	N/A
6/30/2017	N/A	-114	N/A	-102	N/A
3/31/2017	N/A	-117	N/A	-103	N/A
12/31/2016	N/A	-112	N/A	-93	N/A
9/30/2016	N/A	-98	N/A	-87	N/A
6/30/2016	N/A	-87	N/A	-75	N/A
3/31/2016	18	-50	N/A	-80	N/A
12/31/2015	24	-30	N/A	-72	N/A
9/30/2015	30	-16	N/A	-54	N/A
6/30/2015	38	2	N/A	-48	N/A
3/31/2015	29	-6	N/A	6	N/A
12/31/2014	32	-3	N/A	13	N/A
9/30/2014	34	-4	N/A	28	N/A
6/30/2014	33	-5	N/A	34	N/A
3/31/2014	31	-7	N/A	5	N/A
12/31/2013	29	-7	N/A	2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: ARDX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ARDX is expected to become profitable in the next 3 years.

Revenue vs Market: ARDX's revenue (33.7% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: ARDX's revenue (33.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ARDX's Return on Equity is forecast to be very high in 3 years time (109%).

Ardelyx Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Price target increased by 7.1% to US$13.39

Consensus EPS estimates fall by 95%, revenue upgraded

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Consensus estimates of losses per share improve by 10%

Price target increased by 9.5% to US$9.94

Consensus revenue estimates increase by 16%

Recent updates

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 7.1% to US$13.39

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Insider notifies of intention to sell stock

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Ardelyx, Inc. announced that it has received $50 million in funding

Consensus EPS estimates fall by 95%, revenue upgraded

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS misses analyst expectations

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Consensus estimates of losses per share improve by 10%

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Key Executive notifies of intention to sell stock

Price target increased by 9.5% to US$9.94

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Insider notifies of intention to sell stock

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Consensus revenue estimates increase by 16%

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

Price target increased by 10% to US$9.36

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Consensus revenue estimates increase by 17%

New major risk - Shareholder dilution

Price target increased by 7.1% to US$7.58

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Insider notifies of intention to sell stock

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)

Consensus EPS estimates fall by 47%, revenue upgraded

Price target increased by 7.6% to US$7.08

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Consensus revenue estimates increase by 29%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)

Forecast to breakeven in 2024

Ardelyx Provides Update on FDA Appeal for XPHOZAH (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Consensus forecasts updated

Price target increased to US$5.85

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

High number of new directors

Consensus revenue estimates increase by 71%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ardelyx Presents New Data Analyses At Kidney Week 2022, Further Supporting the Clinical Relevance of Xphozah(R) (Tenapanor)

Ardelyx, Inc Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

Ardelyx, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ardelyx, Inc. to Present Poster Presentations on IBSRELA (Tenapanor) for Adult Patients with IBS-C At the American College of Gastroenterology 2022 Annual Scientific Meeting

What To Expect For Ardelyx In The Coming Month

Insider notifies of intention to sell stock

Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position

Consensus forecasts updated

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.45 loss in 2Q 2021)